Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

doi:10.1182/bloodadvances.2020003698

HFCAS OpenIR

	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
	Yang, Haiyan 1; Xiang, Bing 2; Song, Yuqin 3; Zhang, Huilai 4; Zhao, Weili 5; Zou, Dehui 6; Lv, Fangfang 7; Guo, Wei 8; Liu, Aichun 9; Li, Caixia 10; Tan, Ziwen 11,12; Liu, Yang 11,12; Fu, Lina 11,12; Guo, Haiyi 11,12; Novotny, William 11,12; Huang, Jane 11,12; Li, Yufu 13
	2022-03-22
发表期刊	BLOOD ADVANCES
ISSN	2473-9529
通讯作者	Li, Yufu(liyufu439@126.com)
摘要	The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4 patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade $ 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.
DOI	10.1182/bloodadvances.2020003698
关键词[WOS]	NON-HODGKIN-LYMPHOMA ; IMMUNOHISTOCHEMISTRY ; IBRUTINIB ; SURVIVAL
收录类别	SCI
语种	英语
资助项目	BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
项目资助者	BeiGene ; BeiGene Ltd. (Shanghai, China) ; BeiGene USA, Inc. (San Mateo, CA)
WOS研究方向	Hematology
WOS类目	Hematology
WOS记录号	WOS:000792486200001
出版者	ELSEVIER
引用统计	被引频次：20[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130924
专题	中国科学院合肥物质科学研究院
通讯作者	Li, Yufu
作者单位	1.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc,Canc Hosp, Hangzhou, Peoples R China 2.West China Hosp, Sichuan Hosp, Dept Hematol, Chengdu, Peoples R China 3.Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China 4.Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China 5.Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Sch Med,Shanghai Inst Hematol,Ruijin Hosp, Shanghai, Peoples R China 6.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Lymphoma Diag & Therapy Ctr, Tianjin, Peoples R China 7.Fudan Univ, Shanghai Canc Hosp, Dept Oncol, Shanghai, Peoples R China 8.First Hosp Jilin Univ, Dept Hematol & Oncol, Changchun, Peoples R China 9.Harbin Med Univ, Canc Hosp, Dept Hematol & Lymphoma, Harbin, Peoples R China 10.Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China 11.BeiGene Shanghai Co Ltd, Shanghai, Peoples R China 12.BeiGene USA Inc, San Mateo, CA USA 13.Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
推荐引用方式 GB/T 7714	Yang, Haiyan,Xiang, Bing,Song, Yuqin,et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma[J]. BLOOD ADVANCES,2022,6.
APA	Yang, Haiyan.,Xiang, Bing.,Song, Yuqin.,Zhang, Huilai.,Zhao, Weili.,...&Li, Yufu.(2022).Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.BLOOD ADVANCES,6.
MLA	Yang, Haiyan,et al."Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma".BLOOD ADVANCES 6(2022).